Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Innocoll's CollaGUARD dressing:

This article was originally published in Clinica

Executive Summary

Innocoll has received its first regulatory approval in the US, after its wholly-owned subsidiary, Innocoll Pharmaceuticals, gained 510k clearance for its advanced wound care product, CollaGUARD. The collagen-based dressing, which incorporates the firm's CollaRx membrane technology, can be used to manage superficial and deep wounds. The worldwide market for advanced wound care dressings is worth well over $1bn, the Ashburn, Virginia firm said, adding that because CollaGUARD can be manufactured using a "highly efficient and cost-effective process", it can compete "very favourably" against other collagen-based wound care products. CollaGUARD is already approved in Europe. Follow-up products currently in development include a silver-impregnated version of CollaGUARD for infected wounds or wounds at risk of infection, and DermaSIL, a collagen-synthetic foam composite dressing for deep and heavily exuding wounds.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT053431

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel